Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhäuser M, Stadler M, Beelen D, Vucinic V, Burmeister T, Stelljes M, Faul C, Dreger P, Kiani A, Schäfer-Eckart K, Schwerdtfeger R, Lange E, Kubuschok B, Horst HA, Gramatzki M, Brück P, Serve H, Hoelzer D, Gökbuget N, Ottmann OG; GMALL Study Group.
Pfeifer H, et al. Among authors: hoelzer d.
Leukemia. 2013 Jun;27(6):1254-62. doi: 10.1038/leu.2012.352. Epub 2012 Dec 5.
Leukemia. 2013.
PMID: 23212150
Clinical Trial.